Kura Oncology Inc (KURA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Kura Oncology Inc stock $4.79, price $7.09, that is 32.4% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Kura Oncology Inc
KURA · USExpensive (fair value 32% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range $5.54 – $23.53 · fair‑value band $3.59 – $5.99 · the $7.09 price screens above the $4.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Kura Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Show moreShow less
The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
The company is headquartered in San Diego, California.
Stock analysis
Kura Oncology Inc (KURA) currently trades at $7.09, while our estimate is $4.79, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $3.59 (bear) to $5.99 (bull), the price of $7.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kura Oncology Inc reported revenue of $67.5M in FY2025 versus $0 in FY2021. Reported net income was −$279M in FY2025.
Key figures
Market cap $630M Small · P/S ratio 8.71 · EPS (TTM) $−3.30 · Return on equity −225% · Return on assets (EBIT) −31.7% (5-year average) · Operating margin −394% · Revenue (TTM) $79.3M · Revenue growth (YoY) +10.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).
What moves the price
The share trades about 48% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, KURA screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $3.9M, on Nov 16, 2026. Over the same period, 6 people sold shares worth $2.7M.
- BuyTroy Edward WilsonPresident and CEO, Director3× since Aug 17, 2026: 400,000 shares, avg. $9.64$3.9MNov 16, 2026
- SaleBrian T. PowlChief Commercial Officer5× since Jan 27, 2026: 53,548 shares, avg. $10.53$564,109Sep 29, 2026
- SaleMollie LeoniChief Medical Officer3× since Jan 27, 2026: 134,359 shares, avg. $10.00$1.3MSep 29, 2026
- SaleKathleen FordChief Operating Officer3× since Jan 27, 2026: 14,644 shares, avg. $10.09$147,776Sep 29, 2026
- SaleThomas James DoyleSVP, Finance & Accounting2× since Jan 27, 2026: 11,749 shares, avg. $9.26$108,795Sep 28, 2026
- SaleTeresa Brophy BairChief Legal Officer4× since Jan 27, 2026: 53,393 shares, avg. $11.28$602,303Sep 28, 2026
- SaleFrancis BurrowsChief Scientific Officer3× since Dec 18, 2025: 45,763 shares, avg. $10.22$467,594Sep 24, 2026
- SaleFaheem HasnainDirector10,000 shares at $10.98$109,800Dec 9, 202510b5-1 plan
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
- Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
- Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach
- The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today
Compare Kura Oncology Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs KURA |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs KURA |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs KURA |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs KURA |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs KURA |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs KURA |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs KURA |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs KURA |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs KURA |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs KURA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kura Oncology Inc (KURA) overvalued or undervalued?
What is the fair value of KURA?
What is the quality score of KURA?
What is the price target for Kura Oncology Inc (KURA)?
What is the Kura Oncology Inc stock forecast for 2026?
What is the revenue of Kura Oncology Inc (KURA)?
What is the intrinsic value of Kura Oncology Inc (KURA)?
Is Kura Oncology Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of KURA?
How much is Kura Oncology Inc worth?
What do the bullish and bearish scenarios say about KURA?
How solid is the balance sheet of Kura Oncology Inc (KURA)?
How far is KURA from its 52-week high?
Which stocks are comparable to Kura Oncology Inc?
Is Kura Oncology Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Kura Oncology Inc (KURA)?
What should I pay attention to with Kura Oncology Inc right now?
Key figures of Kura Oncology Inc
How large is the market capitalisation of Kura Oncology Inc (KURA)?
What is the P/S ratio of Kura Oncology Inc (KURA)?
What are the earnings per share of Kura Oncology Inc (KURA)?
What is the return on equity of Kura Oncology Inc (KURA)?
What is the EBIT return on assets of Kura Oncology Inc (KURA)?
What is the operating margin of Kura Oncology Inc (KURA)?
How fast is revenue growing at Kura Oncology Inc (KURA)?
How much free cash flow does Kura Oncology Inc (KURA) generate?
How much net cash does Kura Oncology Inc (KURA) hold?
Watch Kura Oncology Inc in the live analysis
One click puts Kura Oncology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.